Gene therapy has remained a constant prospect in the sphere of hemophilia treatment. For over two decades and the question remained: Is this just a dream, or could it one day become a reality?
Hemophilia gene therapy has finally been approved.
David Page talks to hemophilia specialists that will dive deep into understanding how the treatment works, its significance in advancing treatment, and how a one time treatment could change a severe condition to a milder one.Though not a definitive cure, gene therapy for hemophilia has transformed the dream of a cure into a reality for the future.
David and his guests will provide exclusive insights into one of the most significant medical breakthroughs of our era.
Gene therapy—a high-cost, one-time, potentially life-changing treatment—presents unique challenges for governments that make decisions on funding innovative treatments. Dr. Durhane Wong-Rieger presents creative ideas on new ways to think about how gene therapy for hemophilia A and B could be funded in Canada. Durhane is a health coach, frequent lecturer and author. She is the President and CEO of the Canadian Organization for Rare Diseases and chair of Rare Diseases International.
Canadian Hemophilia Society
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.